Myeloma Minute: CAR T-Cell Therapy Results

myelomaMinBanner5.9.19.jpg

| INNOVATION | Latest Research

540x270CarTCellV2.jpg

Good News in a Newly Published CAR T-cell Therapy Study

Response rates and remission lengths were “remarkably good” in a study of myeloma patients treated with the bb2121 anti-BCMA CAR-T cell therapy, says IMF Chairman Dr. Brian G.M. Durie. He reviews the treatment’s safety, anti-myeloma benefit, and, of course, the bottom line in his review of the recent report in The New England Journal of Medicine.

ReadBlogButton.png

| INSPIRATION | Mother’s Day

540x270AmazonMotherDay.jpg

Shop for Mom and Give to the IMF at the Same Time

If you shop Amazon this Mother’s Day (Sunday, May 12) or for your daily needs, visit smile.amazon.com and select the International Myeloma Foundation as your preferred charity. When you shop at this link, Amazon will donate a percentage of your total purchase to the IMF, at no added cost to you. Donating to the IMF this Mother’s Day is as easy as a point-and-click.

ShopNowButton.png

| EDUCATION | Workshop

250x250Detroit.png

| EDUCATION | Publication

250x250tCell.jpg

Register Now for a Regional Community Workshop in Detroit
Hot Off the Press: Myeloma Today!

The IMF will host a Regional Community Workshop at The Westin Book Cadillac Hotel (1114 Washington Blvd) in Detroit, on Saturday, June 15, 2019. Registration is FREE, but seating is limited. Learn from and meet one-on-one with myeloma experts to get answers to your questions and concerns.

The Spring 2019 Myeloma Today is now available as a free download or printed copy. In this edition, Dr. Thomas Martin discusses CAR T-cell therapies in myeloma, including the leading phase II clinical trials of CAR products and the potential advancements in this technology. Select medical articles from Myeloma Today are also available in French, German, Italian, and Spanish.

Register Now Button.png

SubscribeButton.png

| EDUCATION | Nursing Publication

540x270NLBpub.jpg

The IMF’s Nurse Leadership Board Publishes “The Potential of CAR-T Therapy and the Myeloma Patient Journey”

In September 2018, members of the IMF’s Nurse Leadership Board (NLB) who have experience with CAR T-cell therapy convened to discuss anti-B cell Maturation Antigen (BCMA) in the relapsed/refractory multiple myeloma patient-treatment journey. In this paper, the NLB provides insights and education about CAR T-cell therapy. Read the full publication at the link below.

ReadNowButton.png

| INNOVATION | Research Grants

490x245NovisGrant.png

Calling All Researchers: Submit Your Grant Applications

The Brian D. Novis Research Grants honor the IMF’s founder Brian Novis, who succumbed to multiple myeloma in July of 1992. The grants are awarded to researchers working in the field of multiple myeloma and related disorders, including smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), and immunoglobulin-derived amyloidosis. The 2020 grants will support senior research projects with $80,000 each and junior research projects with $50,000 each. The deadline for applications is Thursday, August 1, 2019.

LearnMoreButton.png

| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series

DurieVideoBox5.9.19.png

CLINICAL TRIALS
EVENTS

Search the Myeloma Matrix 2.0

Join the conversation about myeloma on the Smart Patients Message Board

May 11, 2019
Regional Community Workshop
Edina, MN

May 31, 2019
Hiking the Applachian Trail for a Cause
Northeast U.S.

June 1, 2019
12th Annual Czerkies Memorial Golf Outing
Channahon, IL

June 15, 2019
Regional Community Workshop
Detroit, MI

June 29, 2019
Regional Community Workshop
Pittsburgh, PA

subscribe_button.png          donate_button_bottom.png
We Thank Our Sponsors:
Celgene Corporation, Genentech, and Takeda Oncology

We also thank individuals like you for your continued support!

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.